A Kinetic Method for Characterization of Heterogenous Fibrinogen and Its Application to Fibrinogen Grand Rapids, a Congenital Dysfibrinogenemia

D L Higgins; S D Lewis; J A Penner; J A Shafer

doi:10.1055/s-0038-1657252

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1982; 48(02): 182-186
DOI: 10.1055/s-0038-1657252

Original Article

Schattauer GmbH Stuttgart

A Kinetic Method for Characterization of Heterogenous Fibrinogen and Its Application to Fibrinogen Grand Rapids, a Congenital Dysfibrinogenemia

D L Higgins

The Departments of Biological Chemistry and Internal Medicine, The University of Michigan, Ann Arbor, Michigan, U.S.A.

,

S D Lewis

The Departments of Biological Chemistry and Internal Medicine, The University of Michigan, Ann Arbor, Michigan, U.S.A.

,

J A Penner

The Departments of Biological Chemistry and Internal Medicine, The University of Michigan, Ann Arbor, Michigan, U.S.A.

,

J A Shafer

The Departments of Biological Chemistry and Internal Medicine, The University of Michigan, Ann Arbor, Michigan, U.S.A.

› Author Affiliations

Abstract

PDF Download

Summary

A kinetic analysis was developed to determine the steady state kinetic parameter k_cat/K_M for the thrombin-catalyzed release of FPA from abnormal and normal fibrinogen in mixtures of the two. Such mixtures are likely to comprise the fibrinogen of individuals with congenital dysfibrinogenemia. The analysis was used to characterize fibrinogen Grand Rapids, a new congenital dysfibrinogenemia. It indicated that fibrinogen from affected individuals was composed of normal and abnormal fibrinogen in roughly equal amounts, and that the value of k_cat/K_M for the thrombin-catalyzed release of FPA from the fibrinogen variant was 77fold lower than that for the release of FPA from the normal fibrinogen. In separate studies, fibrinogen Grand Rapids was found to exhibit a reduced clottability. Additionally, affected individuals appeared to have plasma fibrinogen concentrations which were about one-third the normal value.

Keywords

Dysfibrinogenemia - Fibrinogen - Fibrinopeptides - Fibrinogen Grand Rapids

PDF (1174 kb)

References

References
1 Mammen EF. Congenital abnormalities of the fibrinogen molecule. Semin Thromb Haemostas 1974; 1: 184-201
2 Crum ED. Abnormal Fibrinogens. In Hemostasis: Biochemistry, Physiology and Pathology. Ogston D, Bennett B. (Eds) John Wiley and Sons Ltd.; New York: 1977: 424-445
3 Morse EE. The fibrinogenopathies. Ann Clin Lab Sci 1978; 8: 234-238
4 Mosesson MW, Sherry S. The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry 1966; 5: 2829-2835
5 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415-443
6 Matsude M, Iwanaga S, Nakamura S. A simple, large scale method for preparation of plasminogen-free fibrinogen. Thromb Res 1972; 1: 619-630
7 Laki K. The polymerization of proteins: The action of thrombin on fibrinogen. Arch Biochem Biophys 1951; 32: 317-324
8 Penner JA. Experience with a thrombin clotting time assay for measuring heparin activity. Am J Clin Pathol 1974; 61: 645-655
9 Quick AJ. The determination of prothrombin by the method of Quick:. In Transactions of the 1st Conference on Blood Clotting and Allied Problems of the Josiah Macy, Jr., Foundation. Flynn JE. (Ed) Josiah Macy Jr. Foundation; New York: 1948: 170-172
10 Nye SW, Graham JB, Brinkhous KM. The partial thromboplastin time as a screening test for the detection of latent bleeders. Am J Med Sci 1962; 243: 279-284
11 von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
12 Foster JBT, Dinatalo A, Lotti LLB. Determination of plasma fibrinogen by means of centrifugation after heating. Am J Clin Pathol 1959; 31: 42-45
13 Biggs R, Macfarlane RC. Human Blood Coagulation and its Disorders. F. A. Davis Co.; Philadelphia: 1962: 392-393
14 Laurell C-B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
15 Higgins DL, Shafer JA. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-Aα16 by a His: Evidence for thrombin-catalyzed hydrolysis at a histidyl residue. J Biol Chem 1981; 256: 12013-12017
16 Higgins DL, Penner JA, Shafer JA. Fibrinogen Petoskey: Identification of a new dysfibrinogenemia characterized by altered release of fibrinopeptide A. Thromb Res 1981; 23: 491-503
17 Gralnick HR, Givelber HM, Shainoff JR, Finlayson JS. Fibrinogen Bethesda: A congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest 1971; 50: 1819-1830
18 McKee PA, Schwartz ML, Pizzo SV, Hill RL. Cross-linking of fibrin by fibrin-stabilizing factor. Ann NY Acad Sci 1972; 202: 127-148
19 Sherman LA, Mosesson MW, Sherry S. Isolation and characterization of the clottable low molecular weight fibrinogen derived by limited plasmin hydrolysis of human fraction I-4. Biochemistry 1969; 8: 1515-1528
20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680-685
21 Mosesson MW, Finlayson JS, Galanakis DK. The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis. J Biol Chem 1973; 218: 7913-7929
22 Bender ML, Kézdy FJ. Mechanism of action of proteolytic enzymes. Ann Rev Biochem 1965; 34: 49-76
23 Brot FE, Bender ML. Use of the specificity constant of α-chymotrypsin. J Am Chem Soc 1969; 91: 7187-7191
24 Fersht A. Enzyme structure and mechanism. Freeman W.H. and Co.; San Frandsco: 1977: 95-97
25 Gralnick HR, Givelber HM, Finlayson JS. A new congenital abnormality of human fibrinogen. Fibrinogen Bethesda II. Thrombos Diathes Haemorrh 1973; 29: 562-571
26 Gralnick HR, Coller BS, Fratantoni FC, Martinez J. Fibrinogen Bethesda III: A hypodysfibrinogenemia. Blood 1979; 53: 28-46
27 Böttcher D, Hasler K, Köttgen E, Maurath J. Hereditary hypodysfibrinogenemia with defective release of fibrinopeptide A (fibrinogen Freiburg). Thromb Haemostas 1979; 42: 78 (Abstr.)
28 Krause WH, Huth K, Heene DL, Lasch HG. Hypodysfibrinogenemia: Fibrinogen Gießen II. Klin Wschr 1975; 53: 781-782
29 Fernandez J, Lasierra J, Narvaiza MJ, Vilades E, Palados E, Rocha E. Fibrinogen Longroño. A new fibrinogen molecular variant. Thromb Haemostas 1979; 42: 138 (Abstr.)
30 Fuchs G, Egbring R, Havemann K. Fibrinogen Marburg: A new genetic variant of fibrinogen. Blut 1977; 34: 107-118
31 Al-Mondhiry HAB, Bilezikian SB, Nossel HL. Fibrinogen “New York” – an abnormal fibrinogen assodated with thromboembolism: Functional evaluation. Blood 1975; 45: 607-619
32 Imperato DIC, Dettori AG. Ipofibrinogenemia congenita con fibrinoastenia. Helv Paediatr Acta 1958; 13: 380-399
33 Martinez J, Holburn RR, Shapiro SS, Erslev AJ. Fibrinogen Philadelphia: A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism. J Clin Invest 1974; 53: 600-611
34 Sherman LA, Gaston LW, Kaplan ME, Spivack AR. Fibrinogen St. Louis: A new inherited fibrinogen variant coinddentally assodated with hemophilia A. J Clin Invest 1972; 51: 590-597
35 Aznar J, Femandez-Pavon A, Reganon E, Vila V, Orellana F. Fibrinogen Valenda, a new case of congenital dysfibrinogenemia. Thrombos Diathes Haemorrh 1974; 32: 564-577
36 Hasselback R, Marion RB, Thomas JW. Congenital hypofibrinogenemia in five members of a family. Can Med Assoc J 1963; 88: 19-22